Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy.
PMID: 26889227
2016
Experimental and therapeutic medicine
Abstract: Clonal analysis further revealed that the rtS202G or rtT184F was in all cases co-localized with rtL180M and rtM204V in any single virus isolate clone.
Abstract: In patient A, the rtL180M, rtS202G and rtM204V mutant variants were detected using pyrosequencing prior to virological breakthrough.
Abstract: In patient B, the rtL180M, rtM204I and
Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China.
PMID: 26876337
2016
The Brazilian journal of infectious diseases
Abstract: Mutations in HBV DNA polymerase were detected in 24 patients (8.9%) including rtM204I/V (n=6), rtN236T (n=5), rtM250V (n=2), rtL180M (n=2), rtT184G (n=1), rtM207I (n=1), rtS202I (n=1), rtM204V/I & rtL180M (n=5), and rtM204I &
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Result: At baseline, this patient displayed rtM204I/V (3.5%), rtL180 M (2.1%), and rtS202G (3.4%) substitutions, and the resistance and nonresistance mutations frequencies were significantly different (P = 0.011).
Result: Eight patients harbored rtM204I/V substitutions of at least 1% (ranging from 1% to 3.6%); 2 of these patients also presented rtL180 M substitutions (2.3% and 2.4%) and rtS202G substitutions (3.2% and 3.5%), whereas the other 6 harbored a low frequency of rtS202G substitut
Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.
Method: Using the Mutation Reporter Tool software (http://hvdr.bioinf.wits.ac.za/mrt/), HBV resistance-associated mutations (RAMs) in the pol gene represented by V173L, L180M, A181V, A194T, S202G, M204V/I and N236T were assessed.
Result: Regarding RAMs, the mutation M204V/I, associated with the compensatory mutation L180M, was significantly more common in genotype HBV/A (
Table: L180M
Discussion: When considering HBV/A genotypes only, we observed a high (~50%) prevalence of M204V/I and L180M mutations.
Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultradeep pyrosequencing.
Result: In all four patients, the M204V mutation was accompanied by the L180M mutation, and an identical trend was observed in the two mutation sites (Table III).
Result: Notably, the mutation rate of rtM204I/V was markedly increased at the time of virological breakthrough in eight patients, and this was accompanied by an increased mutation
Discussion: Additionally, the present study revealed that YVDD-variant-dominated virological breakthrough was closely associated with the L180M mutation, and an identical trend in the changes of the M204V and L180M mutations was observed, which raised the question of the specific mechanism of rt204 and its supplementary sites.
Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.
Abstract: RESULTS: TDF susceptibilities of lamivudine-resistant clones (rtL180M/M204V) and lamivudine plus entecavir-resistant clones (rtL180M/S202G/M204V) were similar to wild type clones in vitro.
Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection.
PMID: 25982306
2015
The Brazilian journal of infectious diseases
Abstract: Of these, nine and eight patients carried lamivudine (LAM)-/telbivudine (LdT)-resistance mutations (rtL180M, rtM204I/V) and adefovir (ADV)-resistance mutations (rtA181T/V, rtN236T), respectively.
Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Abstract: The baseline mutation profiles, rtM204I (p=0.992), rtM204I/V (p=0.177), and rtL180M (p=0.051), were not correlated with the cumulative virological response, and the baseline HBV DNA level (p=0.032) was the only independent predictive factor for cumulative virological response.
Method: LAM-associated mutations including rtL180M and rtM204I/V were identified at the baseline by using the RFMP assay, which was performed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry as described previously.
Discussion: Furthermore, rt
High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Abstract: Three major patterns of mutations in HBV polymerase gene, namely single (rtM204V), double (rtL180M+rtM204V) and triple (rtV173L+rtL180M+rtM204V) mutations, are associated with 3TC-resistance; additionally, the triple mutation has vaccine-escape potential due to a corresponding change in overlapping surface gene.
HBV mutation literature information.
PMID: 
2016
Experimental and therapeutic medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT